We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Venn Life Sciences Holdings Plc | LSE:VENN | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.85 | 6.70 | 7.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
06/1/2017 17:03 | Nothing Dave. That's all that has to happen. I exited a few months back because things weren't imo running quite as expected and I didn't understand or like Beaufort chipping in (in no official capacity) from the sides with 'broker' updates, I might have been wrong but I wondered whether an acquisition and placing might be in the offing, I've learned the hard way to watch out when Beaufort are about:). I'll probably jump back in at some point there's a price for everything, don't mind if I've got it wrong and it suddenly shoots and I hope it does for those who've held. I don't think there's anything wrong with the company just delivery not matching expectations. | paleje | |
06/1/2017 16:59 | It's a dog, Dave.. a dog with a shiny coat which everyone loves to stroke, but when no-one's looking spends most of its time licking its balls. (in other words I don't have a clue but I'm as fed up watching it as you are). | shrout | |
06/1/2017 16:57 | Well not sure really. Is it that the recent contract win was from a company who's director is connected with Venn. Or perhaps the fact that we all thought Innovenn was going to be sold & the proceeds placed in shareholders pockets. Your guess is as good as mine Dave. | cocker | |
06/1/2017 16:35 | One simple question - what the hell has happened here to cause such a collapse in the sp? Now a very nervous holder. | investordave | |
03/1/2017 18:07 | I have had a number of shares over the years which were slow burners, but which did come very good with patience. I remain confident in Venn and think there is bags of upside potentially, though of course nothing is guaranteed. Whilst I would expect Techinvest to tip them in the Jan edition I would not expect it to give the shares much of a boost as they have been pushing them every month for at least a year! | pentangle | |
03/1/2017 17:50 | FFS how much further has this puppy got to go before it re-bounds. 20p my exit price & with Techinvest out next weekend, one would have thought Venn would defo be in their top ten new year tips. Lets hope that's it for the falling share price | cocker | |
14/12/2016 12:35 | We could do with some good news soon from the Company. The share price is drifting down aimlessly and the seeming lack of interest is deafening. Still holding tight but it would be heartening to see some buying for once. | investordave | |
12/12/2016 10:28 | Can we expect another 10000 dump at l055? | investordave | |
10/12/2016 09:07 | The Investor slide deck and the Pathfinder prospectus for the Integumen IPO have been doing the rounds this week, if you ask your broker nicely,they will probably be able to forward copies on to you. It is EIS qualifying, so 30% off the IPO price for UK tax payers, courtesy of HMRC. | timbo003 | |
08/12/2016 13:28 | If the lack of interest in VENN continues, I might have to buy some more shares. | investordave | |
06/12/2016 15:46 | Strangely enough hangman, I can't be bothered to tell you..... | eburne1960 | |
06/12/2016 09:32 | B1ggles. I noticed that too. And perhaps more oddly the article didn't seem to result in a single buy either. It's not a bad thing being under the radar but publicly we seem to be bordering on the non-existent at present. | investordave | |
06/12/2016 08:41 | Hi this may seem a silly question, will shareholders be getting shares inIntegumen, or will VENN be getting them to hold ? Have been away for a while, & can't be bothered to read through all the RNS's | mr hangman | |
05/12/2016 23:17 | I think Venn is unknown, rather than unloved. There's no news to buy into yet. These smaller companies can take ages to get both business traction and investment traction. Given the track record of the CEO, I'm sure there will be a point when the expansion efforts crystallize into clean profits to show obvious shareholder value, otherwise there would be no point in building it as he has been doing. Its not being built by a medical enthusiast with an interest in the products as far as I can see - its being built as a business opportunity by people who know about the market. | yump | |
05/12/2016 21:25 | Appears to be more focus on the share trades rather than the IPO of Integumen! Here's a short update. The holding company Integumen now contains the following assets:- * Labskin – Living human skin equivalent model for pharmaceutical and cosmetic testing (on market) * Clarogel – Novel OTC anti-acne/blemish control product (late stage development). * A disposable oral hygiene product targeted at the professional market. Already selling well in Germany...although I'm unaware if the acquisition of this company has completed yet. * Visible Youth – A premium skin care range with a unique blend of active ingredients supported by scientific evidence. Due to launch H2 2017. * Wound pHase – a chronic wound diagnostic tool based upon a novel pH sensitive hydrogel It is intimated that these collective assets have received c.£15m investment spend up until now, with oral hygiene product already selling in relatively high volume with plans to extend in a number of markets. Will be interesting to learn how much Integumen plan to raise at IPO. Kind regards, GHF | glasshalfull | |
05/12/2016 18:21 | Just seen my above post. There, there. I think I will stick to only using computer in future. | cocker | |
05/12/2016 14:33 | Venn appears to be very unloved at the moment. The lack of investment interest in the Company is v surprising. | investordave | |
05/12/2016 14:32 | Yep fraid so. And the small sales are continuing I see. | investordave | |
25/11/2016 09:12 | I could not have put it better myself LBO. All to often I see companies acquisition's used as a scapegoat for poor management or company failings. The constant amount of Directors running these AIM listed companies for their own end, is far more common these days then when it was back say some ten years ago. It happens because they are almost immune from prosecution & therefore its a free for all. Finding the gem in amongst a pile of rocks gets harder by the day. | cocker | |
25/11/2016 08:42 | You can invest in a below average business with a great management and make a fortune or invest in great business with a below average management team and loose a fortune!!!! And remember the AIM casino as we all know too well has many great business ideas and business plans in which no shareholder value is ever created but rather only destroyed. The lack of regulation allows poor management to continually line their own pockets at shareholders expense. | lbo | |
22/11/2016 17:33 | Apart from understanding the business, the point that LBO makes is relevant I think, in that its worth trying to make sure that you understand the motives of the BOD, regardless of what they say about shareholder value. Then its perhaps possible to align your own strategy to match what you think their's might be and get out at an appropriate time. ie. there's a big difference between the motives of a BOD who are founders, who have worked from scratch to grow a business organically and then bring it to market to make something even bigger, compared to a group of multiple-company directors and ex-fund managers who float something with an acquisition strategy, compared to another group of media guys who claim they are going to change the world with some new fangled thing. | yump |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions